Latest news with #MSNPharmaceuticals
Reuters
16-07-2025
- Business
- Reuters
Novartis cannot block generic version of Entresto, judge rules
July 16 (Reuters) - A federal judge rejected Novartis' (NOVN.S), opens new tab request for a preliminary injunction to stop MSN Pharmaceuticals from selling a generic version of the blockbuster heart medication Entresto. In a decision on Tuesday, U.S. District Judge Evelyn Padin in Newark, New Jersey also reversed her prior ruling that Novartis would likely succeed on its claim of trade dress infringement against the defendant MSN proposed selling a generic version of Entresto under the name Novadoz, which blends the names of Novartis and its Sandoz generics unit. Padin also said Novartis' exclusivity over Entresto may not continue indefinitely, and that "denial of injunctive relief and the availability of a generic alternative to a life-savings medication is in the public interest." Novartis and its lawyers did not immediately respond to requests for comment on Wednesday. The judge said its patent-related exclusivity expires today, July 16.
Yahoo
11-07-2025
- Business
- Yahoo
Novartis loses bid to block US Entresto generic through 2026
By Blake Brittain (Reuters) -Novartis cannot block drugmaker MSN Pharmaceuticals from launching a generic version of its blockbuster heart-failure drug Entresto before its patent expires late next year, a Delaware federal judge said on Friday. U.S. District Judge Richard Andrews rejected Novartis' argument that MSN's generic would infringe one of its patents and denied its request to block the generic from launching until after the patent expires in November 2026. Novartis told the court in a separate filing on Friday that India-based MSN may receive U.S. Food and Drug Administration approval for the generic as soon as July 16 and launch it soon after. The generic would cut into the U.S. market for Swiss-based Novartis' best-selling drug, which earned more than $7.8 billion in global revenue last year. Novartis stock was down more than 2% on Friday morning. The company said in a statement that it was disappointed and planned to appeal. Spokespeople for MSN did not immediately respond to a request for comment. Novartis had convinced the U.S. Court of Appeals for the Federal Circuit in January to halt MSN's launch of its generic until July in a separate patent case.
Reuters
11-07-2025
- Business
- Reuters
Novartis loses bid to block US Entresto generic through 2026
July 11 (Reuters) - Novartis (NOVN.S), opens new tab cannot block drugmaker MSN Pharmaceuticals from launching a generic version of its blockbuster heart-failure drug Entresto through late 2026, a Delaware federal judge said on Friday. U.S. District Judge Richard Andrews rejected Novartis' argument, opens new tab that MSN's generic would infringe one of its patents and denied its request to block the generic from launching until after the patent expires in November 2026. Novartis told the court in a separate filing on Friday that India-based MSN may receive U.S. Food and Drug Administration approval for the generic as soon as July 16 and launch it soon after. The generic would cut into the U.S. market for Switzerland-based Novartis' best-selling drug, which earned the company more than $7.8 billion in global revenue last year according to a company report. Novartis stock was down more than 2% on Friday morning. Spokespeople for Novartis and MSN did not immediately respond to requests for comment on the decision. Novartis had convinced the U.S. Court of Appeals for the Federal Circuit in January to halt MSN's launch of its generic until July in a separate patent case.
